杜瓦卢马布
胆道癌
吉西他滨
耐受性
顺铂
医学
肿瘤科
胆道
内科学
癌症
化疗
不利影响
无容量
免疫疗法
作者
Margherita Rimini,Lorenzo Fornaro,Mario Domenico Rizzato,Lorenzo Antonuzzo,Federico Rossari,Tomoyuki Satake,Hanne Vandeputte,Caterina Vivaldi,Tiziana Pressiani,Jessica Lucchetti,Jin Won Kim,Oluseyi Abidoye,Ilario Giovanni Rapposelli,Stefano Tamberi,Fabian Finkelmeier,Guido Giordano,Federico Nichetti,Hong Jae Chon,Chiara Braconi,Chiara Pirrone
标识
DOI：10.1016/j.ejca.2024.114199
摘要
The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a global multicenter retrospective analysis of its first-line treatment outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
大力的灵雁
eric888
无极微光
你嵙这个期刊没买
lizishu
麦子
小牛马阿欢
热心市民小红花
Winfred
干净的琦
teohsj
随机发
pluto
乐空思
菜狗
Jara
xzy998
2052669099
GingerF
iNk
皖公网安备34019202002308
